These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32940635)

  • 21. Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19.
    Boggiano C; Eisinger RW; Lerner AM; Anderson JM; Woodcock J; Fauci AS; Collins FS
    Ann Intern Med; 2022 Jan; 175(1):119-126. PubMed ID: 34724404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fast-spreading COVID variant can elude immune responses.
    Callaway E
    Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
    [No Abstract]   [Full Text] [Related]  

  • 23. Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors.
    Razafimahatratra SL; Ndiaye MDB; Rasoloharimanana LT; Dussart P; Sahondranirina PH; Randriamanantany ZA; Schoenhals M
    Lancet Glob Health; 2021 Oct; 9(10):e1363-e1364. PubMed ID: 34534478
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High SARS-CoV-2 Seroprevalence in Healthcare Workers in Bukavu, Eastern Democratic Republic of Congo.
    Mukwege D; Byabene AK; Akonkwa EM; Dahma H; Dauby N; Cikwanine Buhendwa JP; Le Coadou A; Montesinos I; Bruyneel M; Cadière GB; Vandenberg O; Van Laethem Y
    Am J Trop Med Hyg; 2021 Feb; 104(4):1526-1530. PubMed ID: 33591936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
    Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
    J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
    Díez JM; Romero C; Cruz M; Vandeberg P; Merritt WK; Pradenas E; Trinité B; Blanco J; Clotet B; Willis T; Gajardo R
    J Infect Dis; 2022 Mar; 225(6):938-946. PubMed ID: 34693968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
    Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
    Viruses; 2021 May; 13(5):. PubMed ID: 34065987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroprevalence of SARS-CoV-2 IgG antibodies in the current COVID-19 pandemic amongst co-workers at a UK renal transplant centre.
    Black JT; Haroon U; Barnes SC; Mayaleh S; Bagul A
    Transpl Int; 2021 Feb; 34(2):382-383. PubMed ID: 33320975
    [No Abstract]   [Full Text] [Related]  

  • 32. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.
    Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S
    Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of SARS-CoV-2 antibodies beyond 6 months in health care workers in Mumbai.
    Singhal T; Shah S; Naik R; Kazi A; Thakkar P
    Indian J Med Microbiol; 2021 Apr; 39(2):267. PubMed ID: 33647334
    [No Abstract]   [Full Text] [Related]  

  • 34. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
    Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-A and SARS-CoV-2: an intriguing association.
    de Freitas Dutra V; Bonet-Bub C; Yokoyama APH; Achkar R; Machado RRG; Assunção M; Candelária G; Soares CP; Fachini RM; Fontão-Wendel R; Hamerschlak N; Reis LFL; Araujo DB; Nudelman V; Pinho JRR; Rizzo LV; Sakashita AM; Scuracchio P; Durigon EL; Wendel S; Kutner JM
    Vox Sang; 2021 May; 116(5):557-563. PubMed ID: 33650690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
    Zou J; Li L; Zheng P; Liang W; Hu S; Zhou S; Wang Y; Zhao J; Yuan D; Liu L; Wu D; Xu M; Zhang F; Zhu M; Wu Z; Cao X; Ni M; Ling X; Wu Y; Kuang Z; Hu M; Li J; Li X; Guo X; Xu T; Jiang H; Gao C; Yu M; Liu J; Zhong N; Zhou J; Huang JA; Jin T; He J
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35108220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure.
    Keitel V; Bode JG; Feldt T; Walker A; Müller L; Kunstein A; Klindt C; Killer A; Senff T; Timm J; Ostermann P; Damagnez M; Lübke N; Adams O; Schaal H; Antoch G; Neubert J; Albrecht P; Meuth S; Elben S; Mohring A; Fischer JC; Bölke E; Hoenig M; Schulz AS; Luedde T; Jensen B
    Front Immunol; 2021; 12():645989. PubMed ID: 34012436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
    Vanhove B; Duvaux O; Rousse J; Royer PJ; Evanno G; Ciron C; Lheriteau E; Vacher L; Gervois N; Oger R; Jacques Y; Conchon S; Salama A; Duchi R; Lagutina I; Perota A; Delahaut P; Ledure M; Paulus M; So RT; Mok CK; Bruzzone R; Bouillet M; Brouard S; Cozzi E; Galli C; Blanchard D; Bach JM; Soulillou JP
    Eur J Immunol; 2021 Jun; 51(6):1412-1422. PubMed ID: 33576494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
    Raturi M; Kusum A; Kala M; Mittal G; Sharma A; Bansal N
    Transfus Clin Biol; 2021 Aug; 28(3):300-302. PubMed ID: 33971318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.